# A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

> **NCT07446439** · PHASE3 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 280 (estimated)

## Conditions studied

- Nausea and Vomiting
- Obesity

## Interventions

- **DRUG:** Tradipitant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07446439
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07446439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07446439, "A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT07446439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*